Company profile for Elicio Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Elicio, based in Cambridge Ma, is committed to transforming the lives of patients & their families by re-engineering the body’s immune response to defeat cancer. By combining expertise in materials science & immunology, Elicio is engineering potent Amphiphile immunotherapies including lymph node targeted cell therapy activators, immunomodulators, & vaccines for an array of aggressive cancers. Elicio was founded to expand & a...
Elicio, based in Cambridge Ma, is committed to transforming the lives of patients & their families by re-engineering the body’s immune response to defeat cancer. By combining expertise in materials science & immunology, Elicio is engineering potent Amphiphile immunotherapies including lymph node targeted cell therapy activators, immunomodulators, & vaccines for an array of aggressive cancers. Elicio was founded to expand & apply the ground-breaking Amphiphile technology invented and developed by Darrell Irvine Ph.D. Elicio’s lead Amphiphile vaccine targeting pancreatic cancer & colorectal cancer will begin initial patient studies in 2020.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
One Kendall Square | Building 1400 West | Suite 14303 Cambridge, MA 02139
Telephone
Telephone
(857) 209-0056
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/19/3190855/0/en/Elicio-Therapeutics-Appoints-Veteran-CMC-and-Technical-Operations-Executive-Marc-J-Wolfgang-as-Chief-Technology-Officer.html

GLOBENEWSWIRE
19 Nov 2025

https://www.globenewswire.com/news-release/2025/11/13/3187803/0/en/Elicio-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Updates.html

GLOBENEWSWIRE
13 Nov 2025

https://www.globenewswire.com/news-release/2025/11/07/3183698/0/en/Elicio-Therapeutics-Reports-Robust-Cytolytic-mKRAS-Specific-T-Cell-Responses-Across-Diverse-Patient-HLA-in-Ongoing-Phase-2-AMPLIFY-7P-Trial-of-ELI-002-7P-and-New-ELI-004-Preclinica.html

GLOBENEWSWIRE
07 Nov 2025

https://www.globenewswire.com/news-release/2025/11/03/3179208/0/en/Elicio-Therapeutics-to-Present-Clinical-and-Preclinical-Data-at-the-SITC-2025-Annual-Meeting.html

GLOBENEWSWIRE
03 Nov 2025

https://www.globenewswire.com/news-release/2025/10/27/3174537/0/en/Elicio-Therapeutics-Reports-Robust-T-cell-Responses-Across-Diverse-HLA-backgrounds-in-Ongoing-Phase-2-AMPLIFY-7P-Trial.html

GLOBENEWSWIRE
27 Oct 2025

https://www.globenewswire.com/news-release/2025/09/29/3157646/0/en/Elicio-Therapeutics-Announces-Investigator-Initiated-Phase-1-Trial-to-be-Conducted-by-Memorial-Sloan-Kettering-Cancer-Center-and-funded-by-The-Lustgarten-Foundation-for-Neoadjuvant.html

GLOBENEWSWIRE
29 Sep 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty